Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.

Auteurs : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ
Jaar : 2022
Journal : Prostate Cancer Prostatic Dis
Volume : 25
Pagina's : 199-207

CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.

Auteurs : Karam A, Mjaess G, Martinez Chanza N, Aoun F, Bou Kheir G, Younes H, Kazzi H, Albisinni S, Roumeguère T
Jaar : 2022
Journal : Cancer Invest
Pagina's : 1-15

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions.

Auteurs : Thouvenin J, Martinez Chanza N, Alhalabi O, Lang H, Tannir NM, Barthélémy P, Malouf GG
Jaar : 2021
Journal : Cancers (Basel)
Volume : 13

Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.

Auteurs : Albisinni S, Martinez Chanza N, Aoun F, Diamand R, Mjaess G, Azzo JM, Esperto F, Bellmunt J, Roumeguère T, DE Nunzio C
Jaar : 2021
Journal : Minerva Urol Nephrol
Volume : 73
Pagina's : 292-298

Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.

Auteurs : Zambrana F, Carril-Ajuria L, Gómez de Liaño A, Martinez Chanza N, Manneh R, Castellano D, de Velasco G
Jaar : 2021
Journal : Cancer Treat Rev
Volume : 99
Pagina's : 102239

Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.

Auteurs : Epaillard N, Parent P, Loriot Y, Lavaud P, Vera-Cea EB, Martinez Chanza N, Rodriguez-Vida A, Dumont C, Lozano R, Llácer C, Ratta R, Oudard S, Thibault C, Auclin E
Jaar : 2021
Journal : Front Oncol
Volume : 11
Pagina's : 671969

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

Auteurs : Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van Den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A
Jaar : 2021
Journal : BMC Cancer
Volume : 21
Pagina's : 1292

An update on the management of metastatic clear-cell renal cell carcinoma: the BSMO Expert panel recommendations

Auteurs : Delafontaine B, De Backer D, Beuselinck B, Debruyne P, DHondt L, Gennigens C, Gil T, Vulsteke C, Martinez Chanza N, Verbiest A, Strijbos M, Van Lancker G, Pelgrims G, Rottey S
Jaar : 2020
Journal : Belgian J Medical Oncology
Volume : 14(2)
Pagina's : 56–70

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.

Auteurs : Martinez Chanza N, Xie W, Issa M, Dzimitrowicz H, Tripathi A, Beuselinck B, Lam E, Zakharia Y, Mckay R, Shah S, Mortazavi A, R Harrison M, Sideris S, Kaymakcalan MD, Abou Alaiwi S, Nassar AH, Nuzzo PV, Hamid A, K Choueiri T, C Harshman L
Jaar : 2020
Journal : J Immunother Cancer
Volume : 8

The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.

Auteurs : Carretero-González A, Lora D, Martín Sobrino I, Sáez Sanz I, Bourlon MT, Anido Herranz U, Martinez Chanza N, Castellano D, de Velasco G
Jaar : 2020
Journal : Cancers (Basel)
Volume : 12

Systematic review of neoadjuvant therapy by immune checkpoint inhibitors before radical cystectomy: where do we stand?

Auteurs : Albisinni S, Aoun F, Diamand R, Mjaess G, Esperto F, Martinez Chanza N, Roumeguère T, DE Nunzio C
Jaar : 2020
Journal : Minerva Urol Nefrol
Volume : 72
Pagina's : 663-672

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.

Auteurs : Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC
Jaar : 2020
Journal : J Immunother Cancer
Volume : 8

Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.

Auteurs : Plouznikoff N, Artigas C, Sideris S, Martinez Chanza N, Gil T, Peltier A, Flamen P
Jaar : 2019
Journal : Ann Nucl Med
Volume : 33
Pagina's : 945-954

Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

Auteurs : Martinez Chanza N, Tripathi A, Harshman LC
Jaar : 2019
Journal : Curr Treat Options Oncol
Volume : 20
Pagina's : 44

Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients.

Auteurs : Sideris S, Aoun F, Martinez Chanza N, Latifyan S, Awada A, Costante G, Gil T
Jaar : 2016
Journal : J Endocrinol Invest
Volume : 39(7)
Pagina's : 729-38